venetoclax-obinutuzumab is superior to chemoimmunotherapy in frontline cll: updates from gaia/cll13
Published 2 years ago • 929 plays • Length 5:00Download video MP4
Download video MP3
Similar videos
-
2:22
gaia/cll13: venetoclax-based combination treatments vs standard chemoimmunotherapy in frontline cll
-
3:06
updated pfs results of the gaia/cll13 trial
-
10:20
eha22: time-limited venetoclax-obinutuzumab /- ibrutinib is superior to chemoimmunotherapy in ...
-
10:24
fixed-duration therapy with venetoclax-obinutuzumab in frontline cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
2:50
gaia/cll13: venetoclax-based time-limited combination therapies in cll
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
1:29
update on gaia trial
-
1:59
acalabrutinib, venetoclax and obinutuzumab upfront for cll
-
1:36
obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in cll
-
3:28
genomic factors influencing patient response to venetoclax-based regimens: analysis from cll13/gaia
-
1:35
cll: venetoclax in combination with obinutuzumab
-
3:15
overview of a phase ib study of venetoclax and obinutuzumab in cll
-
1:54
covid-19 in the gaia/cll13 trial
-
1:07
venetoclax-antibody combinations to come in cll
-
1:26
treating richter’s transformation with venetoclax, obinutuzumab and atezolizumab
-
3:22
combining venetoclax and obinutuzumab in the treatment of cll
-
1:00
reveng: venetoclax and obinutuzumab in cll
-
1:09
majic: venetoclax with acalabrutinib or obinutuzumab in cll